{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:01:04Z","timestamp":1791172864896,"version":"4.1.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC8197071169"],"award-info":[{"award-number":["NSFC8197071169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M702340"],"award-info":[{"award-number":["2021M702340"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2023SCU12047"],"award-info":[{"award-number":["2023SCU12047"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Science and Technology Program","award":["2021ZYCD016"],"award-info":[{"award-number":["2021ZYCD016"]}]},{"name":"Sichuan Science and Technology Program","award":["2020YFS0573"],"award-info":[{"award-number":["2020YFS0573"]}]},{"name":"Sichuan Science and Technology Program","award":["2022NSFSC1441"],"award-info":[{"award-number":["2022NSFSC1441"]}]},{"name":"Sichuan Science and Technology Program","award":["2023YFS0123"],"award-info":[{"award-number":["2023YFS0123"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) accounts for the vast majority of thyroid-related mortality and, until recently, there were limited preclinical models for iodine uptake prediction. In the current study, we aim to establish a primary tumor-derived organoid model of DTC and predict radioiodine (RAI) uptake of tumor residue. The genotypic and phenotypic features between organoid and parental tissue were compared. The RAI uptake assay was used to evaluate the organoid's RAI uptake capacity, and related patients' RAI whole-body scans were used to verify the assay's predictive sensitivity. A total of 20 patient-derived DTC organoids have been established. Whole-exome sequencing and immunofluorescence analysis demonstrated that organoids faithfully recapitulated main features of the original tumor tissue. RAI-avid organoids (n = 11) presented significantly higher RAI uptake than the RAI-refractory (RAI-R) group (n = 9; 384.4 \u00b1 102.7 vs 54.2 \u00b1 13.2 cpm\/105 cells, P &amp;lt; .0001). A threshold value in organoids of less than 250 cpm\/105 cell was found to have a predictive sensitivity of 95.0% for distinguishing RAI-R from RAI-avid patients when paired to clinical information. Notably, we found that several tyrosine kinase inhibitors moderately re-sensitize iodine uptake by using organoids derived from 3 patients with different genetic mutation backgrounds. In conclusion, patient-derived DTC organoids recapitulated the main characteristics of their parental tissues and preserved ability to uptake radioiodine, showing potential in the development of novel drugs to boost iodine avidity.<\/jats:p>","DOI":"10.1210\/endocr\/bqae162","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:22:25Z","timestamp":1733815345000},"source":"Crossref","is-referenced-by-count":7,"title":["Modeling Clinical Radioiodine Uptake By Using Organoids Derived From Differentiated Thyroid Cancer"],"prefix":"10.1210","volume":"166","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]},{"name":"Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]},{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]},{"name":"Laboratory of Thyroid and Parathyroid diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyun","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-2635","authenticated-orcid":false,"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-3954","authenticated-orcid":false,"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]},{"name":"Laboratory of Thyroid and Parathyroid diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-0528","authenticated-orcid":false,"given":"Rui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, West China Hospital, Sichuan University , Chengdu 610000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"11","key":"2024123107454889600_bqae162-B1","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jcem.86.11.8048","article-title":"Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake","volume":"86","author":"Castro","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024123107454889600_bqae162-B2","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024123107454889600_bqae162-B3","first-page":"1551","article-title":"Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma","volume":"39","author":"Alexander","year":"1998","journal-title":"J Nucl Med"},{"issue":"8","key":"2024123107454889600_bqae162-B4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1089\/thy.2016.0655","article-title":"Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role?","volume":"27","author":"Silva-Vieira","year":"2017","journal-title":"Thyroid"},{"issue":"7","key":"2024123107454889600_bqae162-B5","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"issue":"5","key":"2024123107454889600_bqae162-B6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"2024123107454889600_bqae162-B7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"issue":"1","key":"2024123107454889600_bqae162-B8","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2024123107454889600_bqae162-B9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/clinem\/dgab020","article-title":"Organoid cultures derived from patients with papillary thyroid cancer","volume":"106","author":"Chen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024123107454889600_bqae162-B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-022-03848-z","article-title":"Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"2024123107454889600_bqae162-B11","doi-asserted-by":"crossref","first-page":"1140888","DOI":"10.3389\/fendo.2023.1140888","article-title":"Establishment of papillary thyroid cancer organoid lines from clinical specimens","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024123107454889600_bqae162-B12","doi-asserted-by":"crossref","first-page":"155670","DOI":"10.1016\/j.phymed.2024.155670","article-title":"The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy","volume":"129","author":"Mi","year":"2024","journal-title":"Phytomedicine"},{"issue":"11","key":"2024123107454889600_bqae162-B13","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/cancers12113212","article-title":"Patient-Derived papillary thyroid cancer organoids for radioactive iodine refractory screening","volume":"12","author":"Sondorp","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024123107454889600_bqae162-B14","doi-asserted-by":"publisher","DOI":"10.17632\/pc88nwxwh2.1","article-title":"Supplementary files for \u201cModeling clinical radioiodine uptake by using organoids derived from differentiated thyroid cancer\u201d","author":"Zhang","year":"2024","journal-title":"Mendeley Data"},{"issue":"8","key":"2024123107454889600_bqae162-B15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/RLU.0000000000000498","article-title":"BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma","volume":"39","author":"Yang","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2024123107454889600_bqae162-B16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"issue":"6","key":"2024123107454889600_bqae162-B17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00259-002-0785-6","article-title":"Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I","volume":"29","author":"Hilditch","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024123107454889600_bqae162-B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-Derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2024123107454889600_bqae162-B19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"issue":"9","key":"2024123107454889600_bqae162-B20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"2024123107454889600_bqae162-B21","doi-asserted-by":"crossref","first-page":"e2103999","DOI":"10.1002\/advs.202103999","article-title":"Patient-Derived upper tract urothelial carcinoma organoids as a platform for drug screening","volume":"9","author":"Li","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"13","key":"2024123107454889600_bqae162-B22","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.7150\/thno.57689","article-title":"Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS","volume":"11","author":"Oh","year":"2021","journal-title":"Theranostics"},{"issue":"11","key":"2024123107454889600_bqae162-B23","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2024123107454889600_bqae162-B24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.surg.2019.04.076","article-title":"Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro","volume":"167","author":"Ullmann","year":"2020","journal-title":"Surgery"},{"issue":"19","key":"2024123107454889600_bqae162-B25","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2024123107454889600_bqae162-B26","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024123107454889600_bqae162-B27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-023-03414-7","article-title":"Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer","volume":"82","author":"Nilsson","year":"2023","journal-title":"Endocrine"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae162\/61023581\/bqae162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/1\/bqae162\/61023581\/bqae162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/1\/bqae162\/61023581\/bqae162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:46:09Z","timestamp":1735613169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae162\/7920648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae162","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,26]]},"article-number":"bqae162"}}